| A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) | |
| Duehrsen, Ulrich; Younes, Anas; Sehn, Laurie H.; Johnson, Peter; Zinzani, Pier Luigi; Hong, Xiaonan; Zhu, Jun; Samoilova, Olga; Suh, Cheolwon; Matsumura, Itaru | |
| 2018 | |
| 卷号 | 132 |
| 会议录 | BLOOD
 |
| 语种 | 英语 |
| URL标识 | 查看原文 |
| ISSN号 | 0006-4971 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3599740 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Duehrsen, Ulrich,Younes, Anas,Sehn, Laurie H.,et al. A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)[C]. 见:. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论